Thursday 14 December 2017
Contact US    |    Archive
PR
3 months ago

Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis

Prometic moving immediately to formalize enrollment of specialist clinical sites across the United S

Read on the original site


Hashtags:   

Prometic

 | 

receives

 | 

FDA

 | 

clearance

 | 

its

 | 

IND

 | 

initiate

 | 

pivotal

 | 

PBI

 | 

4050

 | 
Most Popular (6 hours)

Most Popular (24 hours)

Most Popular (a week)

Categories - Countries
All News
All Countries